Back to Newsroom

Novavax to Host an RSV F Vaccine Update Conference Call and Webcast on July 24, 2017 at 4:30 PM

GAITHERSBURG, Md., July 17, 2017 /PRNewswire/ — Novavax, Inc. (Nasdaq:NVAX) today announced it will host a conference call and webcast on Monday, July 24, 2017, at 4:30 p.m. ET.  Novavax anticipates receiving results and announcing topline data from its Phase 2 safety and immunogenicity trial of the RSV F Vaccine in older adults (60 years of age and older).  In addition, management will provide an update on its prior Phase 2 and Phase 3 clinical trials in older adults and well as its RSV Phase 3 clinical trial for infants via maternal immunization, known as Prepare™, which continues to experience significant acceleration in enrollment and enhanced momentum heading into its third global season.